Suppression of hippocampal GABAergic transmission impairs memory in rodent models of Alzheimer's disease.

Autor: Bie B; Department of Pain Management, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Wu J; Department of Pain Management, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Lin F; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Naguib M; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, 44195, USA., Xu J; Department of Pain Management, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. Electronic address: xuj3@ccf.org.
Jazyk: angličtina
Zdroj: European journal of pharmacology [Eur J Pharmacol] 2022 Feb 15; Vol. 917, pp. 174771. Date of Electronic Publication: 2022 Jan 15.
DOI: 10.1016/j.ejphar.2022.174771
Abstrakt: Emerging evidence demonstrates the potential involvement of hippocampal GABAergic transmission in the process of memory acquisition and consolidation, while no consistent report is available to address the adaptation of hippocampal GABAergic transmission and its contribution to memory deficiency in the setting of Alzheimer's disease (AD). Brain-derived neurotrophic factor (BDNF) is a key molecule that regulates GABAergic transmission. In the brain, mature BDNF is generated from the proteolytic cleavage of proBDNF, while BDNF and proBDNF have differential effects on central GABAergic transmission. First, the present study reports a remarkable increase of proBDNF/BNDF ratio in the hippocampal CA1 area in rodent models of AD, indicating a potential impaired process of BDNF maturation from proBDNF cleavage. We report a suppressed hippocampal GABAergic strength, potentially resulting from the reduced expression of anion chloride co-transporter KCC2 and subsequent positive shift of GABAergic Cl-equilibrium potential (E Cl -), which is attenuated by microinjection of BDNF with proBDNF inhibitor TAT-Pep5. We also show that normalization of proBDNF/BDNF signaling or GABAergic E Cl -by intracerebroventricular (i.c.v.) administration of bumetanide remarkably improves the cognitive performance in Morris water maze test and fear conditioning test in rodent models of AD. These results demonstrate a critical role of hippocampal proBDNF/BDNF in regulating GABAergic transmission and contributing to memory dysfunction in rodent models of AD.
(Copyright © 2022. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: